Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Short Interest Update

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) was the target of a large increase in short interest during the month of November. As of November 15th, there was short interest totalling 3,750,000 shares, an increase of 7.1% from the October 31st total of 3,500,000 shares. Based on an average daily volume of 336,300 shares, the short-interest ratio is presently 11.2 days. Currently, 14.5% of the company’s shares are short sold.

Analyst Upgrades and Downgrades

INO has been the topic of a number of analyst reports. Royal Bank of Canada reduced their price target on Inovio Pharmaceuticals from $7.00 to $6.00 and set a “sector perform” rating on the stock in a research report on Friday, November 15th. Oppenheimer reduced their target price on Inovio Pharmaceuticals from $33.00 to $15.00 and set an “outperform” rating on the stock in a report on Monday, November 18th. Finally, HC Wainwright lowered their price target on shares of Inovio Pharmaceuticals from $12.00 to $5.00 and set a “neutral” rating for the company in a report on Monday, November 18th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $38.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the stock. Cornercap Investment Counsel Inc. acquired a new stake in Inovio Pharmaceuticals in the second quarter valued at approximately $184,000. Bank of New York Mellon Corp acquired a new stake in Inovio Pharmaceuticals in the 2nd quarter valued at $661,000. American Century Companies Inc. increased its stake in Inovio Pharmaceuticals by 62.2% during the 2nd quarter. American Century Companies Inc. now owns 31,565 shares of the biopharmaceutical company’s stock valued at $255,000 after purchasing an additional 12,100 shares in the last quarter. Signature Estate & Investment Advisors LLC bought a new stake in Inovio Pharmaceuticals during the 2nd quarter valued at $88,000. Finally, Dimensional Fund Advisors LP acquired a new position in Inovio Pharmaceuticals during the second quarter worth $605,000. 26.79% of the stock is owned by institutional investors.

Inovio Pharmaceuticals Price Performance

Shares of INO opened at $4.20 on Wednesday. Inovio Pharmaceuticals has a 52-week low of $3.85 and a 52-week high of $14.75. The business’s 50 day moving average price is $5.18 and its two-hundred day moving average price is $7.50.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.